Abstract
Background Stevens-Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN) is a spectrum of severe drug reactions that has a high in-hospital mortality from 5% to 20%. Early risk prediction for in-hospital mortality in SJS/TEN can be informative for clinical management. This study aimed to develop an in-hospital mortality risk calculator for SJS based on patient comorbidities.
Methods Patients who were diagnosed with SJS/TEN were identified in the National Inpatient Sample database between Q4 2015-2020. SJS patients were randomly sampled into two equal experimental and validation groups. The weight for each comorbidity was determined from a multivariable logistic regression to develop into a single SJS Index.
Results There were 4519 SJS (mortality rate 5.05%), 873 SJS-TEN (mortality rate 13.06%), and 759 TEN (mortality rate 17.00%) patients identified. The SJS Index had good discrimination power (c-statistic=0.704, 95% CI=0.656-0.753) and was well-calibrated (Brier score=0.049). SJS Index had similar performance in multivariable regression model with all comorbidities (DeLong p-value=0.621) and validation group (DeLong p-value=0.634). The index had significantly better discriminative power than Elixhauser Comorbidity Index (ECI) (DeLong p-value=0.001). Applying the SJS Index to SJS-TEN patients showed comparable discriminative powers (DeLong test p-value=0.284). In TEN patients, SJS Index remained good calibration (Brier score=0.062) but discriminative power decreased (DeLong p-value=0.005). After adjusting for age, race, and ethnicity, SJS Index had improved performance in all groups.
Conclusions The SJS Index can effectively discriminate and predict in-hospital mortality in SJS and was externally validated in NIS. SJS/TEN often has emergent presentation and immediate intervention is required, this risk score can give an initial assessment of the mortality based on medical records alone and thus offer a quick insight for clinicians for management. In addition, this study demonstrated the possibility of the SJS Index being used as one composite metric to develop a more comprehensive risk-calculator score.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of The George Washington University School of Medicine and Health Sciences waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
